Observational studyTransfusion2026
Demand for human leukocyte antigen or human platelet antigen-selected platelets: An observational study at Canadian Blood Services.
Observational study in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPlatelet transfusion refractoriness (PTR) is a clinically important condition. The Human Leukocyte Antigen and Human Platelet Antigen (HLA/HPA) Platelet Program at Canadian Blood Services (CBS) provides platelet products to support such patients. This study provides a blood operator perspective on the provision of products for the management of immune-mediated PTR (iPTR), including the evaluation of patient data to determine trends in the prevalence and diagnoses associated with iPTR. STUDY DESIGN AND
methodsA retrospective observational study of patients enrolled in the CBS HLA/HPA Platelet Program between April 2021 and March 2025. Patient demographics and platelet product issuance were extracted from internal electronic records. Descriptive statistics were utilized for baseline characteristics and linear regression for temporal trends.
resultsWe identified 788 cases representing 688 unique patients. Median patient age was 60.5 years. The most frequent diagnoses were acute leukemia (44%) and myelodysplastic syndrome (15%). HLA/HPA platelet issuance showed a statistically significant upward trend (average increase 23 units/quarter, p = .004). Platelet requests strongly predicted units issued (R DISCUSSION: The CBS HLA/HPA Platelet Program has experienced a rise in product demand. The strong relationship between product requests and issuance demonstrates the responsiveness of this program, though variability in fill rates and the limited predictive value of case counts highlight ongoing operational challenges. These findings can inform strategies for donor recruitment, inventory management, and case management to ensure reliable access to compatible platelets for sensitized patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.